Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/3/2025

Chalazion Treatment Guidelines

Initial Management

  • The American Academy of Ophthalmology recommends starting with warm compresses applied for 5-10 minutes several times daily combined with eyelid hygiene as first-line therapy for all chalazia 1, 2
  • Apply warm compresses to the affected eyelid for 5-10 minutes, 3-4 times daily, to promote drainage of the obstructed meibomian gland 1, 2
  • Perform gentle massage of the affected area after warm compresses to help express the obstructed gland 1
  • Institute eyelid hygiene by cleaning the eyelid margins with mild soap or commercial eyelid cleansers 1

Treatment Escalation

  • Do not continue conservative management beyond 4-6 weeks without reassessment, as this delays diagnosis of potential malignancy 1
  • Inject triamcinolone acetonide directly into the lesion as the next step before surgery for persistent chalazia after 4-6 weeks of conservative therapy 1, 3
  • Re-evaluate within a few weeks to assess response and check intraocular pressure after intralesional steroid injection 3

Critical Red Flags

  • Always biopsy chalazia with recurrence in the same location, especially in elderly patients, to exclude sebaceous carcinoma 1, 2, 3
  • Biopsy chalazia with marked asymmetry or resistance to standard therapy to exclude sebaceous carcinoma 1, 3
  • Biopsy unifocal recurrent chalazia unresponsive to therapy to exclude sebaceous carcinoma 1
  • Biopsy chalazia with atypical features, including eyelid margin distortion, focal lash loss, or ulceration, to exclude sebaceous carcinoma 1, 3
  • Biopsy unilateral chronic blepharitis unresponsive to therapy to exclude sebaceous carcinoma 2

Addressing Underlying Conditions

  • Treat any associated bacterial blepharitis or meibomian gland dysfunction before addressing the chalazion, as these are common predisposing factors 1
  • Evaluate for meibomian gland dysfunction, rosacea, or seborrheic dermatitis in patients with recurrent chalazia 2
  • Institute regular eyelid hygiene for patients with blepharitis 4, 5
  • Consider systemic antibiotics for severe underlying blepharitis 4, 5

Emerging Treatment Options

  • Intense pulsed light (IPL) with meibomian gland expression shows promise as a non-surgical option for recurrent multiple chalazia resistant to conventional therapy 1, 3
  • Vectored thermal pulsation therapy may improve meibomian gland function 6

Pediatric Considerations

  • Children with chalazia should be evaluated for chronic blepharokeratoconjunctivitis, which is often unrecognized and may present with recurrent conjunctivitis, keratitis, neovascularization, and eyelid inflammation 1, 3, 4
  • Refer to ophthalmology if there is visual loss, moderate/severe pain, or severe/chronic redness in children with chalazia 3

Prevention Strategies

  • Maintain regular eyelid hygiene for patients prone to recurrent chalazia, especially those with blepharitis or meibomian gland dysfunction 1, 2
  • Treat underlying skin conditions, such as rosacea or seborrheic dermatitis, to prevent recurrent chalazia 2
  • Avoid eye makeup during active inflammation to prevent recurrent chalazia 2

Chalazion Management Guideline

Diagnostic Considerations

  • The American Academy of Ophthalmology recommends biopsying chalazia with features such as recurrence in the same location, particularly in elderly patients, to exclude sebaceous carcinoma 7
  • Intense pulsed light (IPL) with meibomian gland expression shows promise as a non-surgical option for recurrent multiple chalazia resistant to conventional therapy, with high Demodex eradication rates and improved meibum quality compared to topical treatments 7
  • IPL should be used with caution in darkly pigmented individuals (above Fitzpatrick skin type IV) due to risk of burns and pigmentation changes 7

Treatment Options

  • Intralesional steroid injection achieves a 93.8% success rate compared to 58.3% with conservative management alone, although common pitfalls include hypopigmentary skin changes at the injection site 7

REFERENCES

1

Chalazion and Hordeolum Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Chalazion and Hordeolum Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Treatment of Chalazion [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025